Tenderwize
Wróć do wyszukiwania

Open-house rebate agreement for Roxithromycin

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Mar 31, 2027 · 217 days left·Open·Supplies
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Roxithromycin, ATC J01FA06

62/100

Ocena szansy

Needs reviewMedium complexity
SuppliesOpen
Skąd ta ocena?

Szansa

62 / 100

Złożoność

58 / 100

Czynniki ryzyka

The notice requires original submission and states that electronic submission is not allowed, which increases the risk...

Only authorised and marketable medicinal products in Germany are eligible, and additional AMIce/Lauer-Taxe evidence may...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Non-exclusive open-house rebate agreements for pharmaceutical products containing Roxithromycin (ATC J01FA06).
  • Supply of authorised and marketable medicinal products in Germany under uniform contract conditions.
Pokaż pełne podsumowanie

Open-house supply arrangement for Roxithromycin (ATC J01FA06) pharmaceutical products by AOK Rheinland-Pfalz/Saarland. The notice states that interested pharmaceutical companies may join on equal terms, with no individual negotiations and no selection decision. The contract period runs from 01.06.2025 to 31.05.2027, with monthly entry possible, but the first submission deadline for the initial start date was 30.04.2025. No contract value is stated. The procedure is explicitly described as not constituting a public procurement contract under the procurement rules, although it is published in TED for transparency.

Ryzyka

The notice requires original submission and states that electronic submission is not allowed, which increases the risk...

Only authorised and marketable medicinal products in Germany are eligible, and additional AMIce/Lauer-Taxe evidence may...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Only authorised and marketable medicinal products in Germany may be supplied.

Administrative

  • If a product is not listed in Lauer-Taxe at submission time, an AMIce public extract must be provided.
  • The AMIce extract must show product name, marketing authorisation holder or authorised manufacturer, dosage form, active substance, and marketability.

Zamawiający

Lokalizacja

Eisenberg, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE271900642

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreement for Roxithromycin

Single lot covering non-exclusive open-house rebate agreements for medicinal products containing Roxithromycin (ATC J01FA06). The scope excludes paediatric medicines listed in the BfArM list under Section 35(5a) SGB V. Contract terms are uniform for all participants; no individual negotiations are conducted. Contracts can start on the first day of a month within the 24-month period, with a maximum duration of 24 months from the earliest start date. The lot information is explicit in the structured data and notice text.

SuppliesEU fundedElectronic submission

Lokalizacja

Eisenberg, Germany

Czas trwania

May 2025 - May 2027

Kategoria

Pharmaceutical products

Termin

Deadline Mar 31, 2027

Szczegóły zamówienia

Data publikacji
10 Apr 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
236088-2025

Dokumenty (1)

Podobne przetargi